Grifols (NASDAQ:GRFS) Reaches New 12-Month Low – Should You Sell?

Posted by Brian Himes on Jun 8th, 2026

Grifols, S.A. (NASDAQ:GRFS – Get Free Report) hit a new 52-week low on Monday . The stock traded as low as $7.37 and last traded at $7.3750, with a volume of 326041 shares trading hands. The stock had previously closed at $7.64.

Wall Street Analyst Weigh In

GRFS has been the topic of a number of recent analyst reports. Weiss Ratings raised shares of Grifols from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. Wall Street Zen lowered shares of Grifols from a “buy” rating to a “hold” rating in a research report on Monday, May 18th. Finally, Zacks Research cut shares of Grifols from a “hold” rating to a “strong sell” rating in a research report on Friday, May 8th. Three analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Grifols currently has an average rating of “Reduce” and an average target price of $10.00.

Check Out Our Latest Analysis on GRFS

Grifols Price Performance

The stock has a market cap of $5.00 billion, a PE ratio of 38.71, a P/E/G ratio of 0.30 and a beta of 0.65. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.47 and a quick ratio of 0.85. The firm’s 50 day moving average price is $8.05 and its two-hundred day moving average price is $8.60.

Grifols (NASDAQ:GRFS – Get Free Report) last released its quarterly earnings data on Saturday, February 14th. The biotechnology company reported $0.38 earnings per share for the quarter. The business had revenue of $2.32 billion during the quarter. Grifols had a net margin of 5.54% and a return on equity of 6.21%. On average, research analysts expect that Grifols, S.A. will post 1.06 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Brandes Investment Partners LP grew its position in Grifols by 6.3% in the fourth quarter. Brandes Investment Partners LP now owns 30,954,223 shares of the biotechnology company’s stock worth $289,422,000 after acquiring an additional 1,838,727 shares in the last quarter. Capital World Investors grew its position in Grifols by 5.9% in the third quarter. Capital World Investors now owns 22,926,140 shares of the biotechnology company’s stock worth $228,344,000 after acquiring an additional 1,273,391 shares in the last quarter. Permian Investment Partners LP grew its position in Grifols by 4.2% in the fourth quarter. Permian Investment Partners LP now owns 18,190,262 shares of the biotechnology company’s stock worth $170,079,000 after acquiring an additional 737,941 shares in the last quarter. Millennium Management LLC grew its position in Grifols by 2.7% in the fourth quarter. Millennium Management LLC now owns 7,122,155 shares of the biotechnology company’s stock worth $66,592,000 after acquiring an additional 184,874 shares in the last quarter. Finally, Bank of Montreal Can boosted its position in Grifols by 45.8% during the fourth quarter. Bank of Montreal Can now owns 4,394,750 shares of the biotechnology company’s stock valued at $41,091,000 after buying an additional 1,381,027 shares during the period.

Grifols Company Profile

(Get Free Report)

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.